E-Therapeutics’ ETX-312: New Data Supporting Disease-Modifying Treatment for MASH
E-therapeutics presented preclinical data at the European Association for the Study of the Liver (EASL) Congress on ETX-312, a...
Alkeus Presents Gildeuretinol Data at ARVO 2025
Alkeus Pharmaceuticals released additional Phase 2 clinical trial (SAGA) data for gildeuretinol, an oral treatment for geographic atrophy (GA)...
Inspira Art100 System Approved for Organ Transplant Patients
Inspira Technologies’ INSPIRA™ ART100 system has been approved for clinical validation by Israel’s largest healthcare provider during organ transplant...
Alterity Therapeutics at International MSA Congress
Alterity Therapeutics will present data from its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) at...
Preclinical Data on Assembly Biosciences’ HBV and HDV Inhibitors at EASL 2025
Assembly Biosciences presented preclinical and in vitro data for two hepatitis drug candidates, ABI-6250 and ABI-4334, at the European...
Alzamend Neuro and Qmenta in AI Imaging Trial
Alzamend Neuro is partnering with QMENTA to utilize their AI-driven imaging platform in five upcoming Phase II clinical trials...
Dr. Falk Pharma PSC Trial Shows Positive Results
Dr. Falk Pharma announced positive 96-week results from its phase 3 NUC-5 trial of norucholic acid (NCA) for primary...
Arbutus Presents Promising HBV Data at EASL 2025
Arbutus Biopharma presented promising data at the EASL Congress 2025 for its chronic hepatitis B (cHBV) treatments, imdusiran and...
Bluejay Therapeutics Unveils Promising NASH Drug Data
Bluejay Therapeutics has revealed preclinical data on BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor designed to treat metabolic...
Clinuvel Recruits 200 Patients in Phase III Vitiligo Trial
Clinuvel Pharmaceuticals completed enrollment of over 200 patients in its Phase III trial (CUV105) for SCENESSE® (afamelanotide 16mg) as...